Company intelligence / Profile preview

Sengenics

United States

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Sengenics has enabled hundreds of published studies utilizing its KREX platform for high-sensitivity autoantibody biomarker discovery and quantitative immunoprofiling; its services are used widely in research, with growing cancer and autoimmune biomarker applications[1][3][4].

Therapeutic areas: OncologyNeurologyInfectious DiseasesImmunology
Modalities: ProteinRecombinant proteinDiagnostic (platform for autoantibody/biomarker discovery)
Industry: Protein Biomarker Diagnostics

Partnerships

Collaborations with top biopharma companiesCollaborations with leading cancer research institutes

Beyond the preview

Go deeper on Sengenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sengenics.

Explore the full profile